Biblio

Export 12 results:
Author Title Type [ Year(Asc)]
Filters: Keyword is Antipsychotic Agents  [Clear All Filters]
2024
G. Alva, Cubała, W. J., Berrio, A., Coate, B., Abler, V., and Pathak, S., “Safety Profile of Pimavanserin Therapy in Elderly Patients with Neurodegenerative Disease-Related Neuropsychiatric Symptoms: A Phase 3B Study.”, J Alzheimers Dis, vol. 98, no. 1, pp. 265-274, 2024.
2021
J. Hartmann, Roßmeier, C., Riedl, L., Dorn, B., Fischer, J., Slawik, T., Fleischhaker, M., Hartmann, F., Egert-Schwender, S., Kehl, V., Haller, B., Schneider-Schelte, H., Dinkel, A., Jox, R. J., and Diehl-Schmid, J., “Quality of Life in Advanced Dementia with Late Onset, Young Onset, and Very Young Onset.”, J Alzheimers Dis, vol. 80, no. 1, pp. 283-297, 2021.
2018
P. Chatterjee, Roy, D., and Rathi, N., “Epigenetic Drug Repositioning for Alzheimer's Disease Based on Epigenetic Targets in Human Interactome.”, J Alzheimers Dis, vol. 61, no. 1, pp. 53-65, 2018.
G. K. Wilcock, Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., Davis, C. S., Staff, R. T., Vuksanovic, V., Ahearn, T., Bracoud, L., Shamsi, K., Marek, K., Seibyl, J., Riedel, G., Storey, J. M. D., Harrington, C. R., and Wischik, C. M., “Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.”, J Alzheimers Dis, vol. 61, no. 1, pp. 435-457, 2018.
D. Addesi, Maio, R., Smirne, N., Laganà, V., Altomari, N., Puccio, G., Colao, R., Cupidi, C., Perticone, F., and Bruni, A. Cecilia, “Prevalence of Delirium in a Population of Elderly Outpatients with Dementia: A Retrospective Study.”, J Alzheimers Dis, vol. 61, no. 1, pp. 251-257, 2018.
2016
T. Nagata, Shinagawa, S., Nakajima, S., Plitman, E., Mihashi, Y., Hayashi, S., Mimura, M., and Nakayama, K., “Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study.”, J Alzheimers Dis, vol. 50, no. 3, pp. 839-45, 2016.
T. Porter, Bharadwaj, P., Groth, D., Paxman, A., Laws, S. M., Martins, R. N., and Verdile, G., “The Effects of Latrepirdine on Amyloid-β Aggregation and Toxicity.”, J Alzheimers Dis, vol. 50, no. 3, pp. 895-905, 2016.
L. Saarelainen, Taipale, H., Koponen, M., Tanskanen, A., Tolppanen, A. - M., Tiihonen, J., and Hartikainen, S., “The Incidence of Benzodiazepine and Related Drug Use in Persons with and without Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 3, pp. 809-18, 2016.
A. Shelef, Barak, Y., Berger, U., Paleacu, D., Tadger, S., Plopsky, I., and Baruch, Y., “Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study.”, J Alzheimers Dis, vol. 51, no. 1, pp. 15-9, 2016.
M. Tong, Deochand, C., Didsbury, J., and de la Monte, S. M., “T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 123-38, 2016.
A. Nørgaard, Jensen-Dahm, C., Gasse, C., Hansen, H. Vibe, and Waldemar, G., “Time trends in antipsychotic drug use in patients with dementia: a nationwide study.”, J Alzheimers Dis, vol. 49, no. 1, pp. 211-20, 2016.
F. Pasquier, Sadowsky, C., Holstein, A., Leterme, G. Le Prince, Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., and J Ryan, M., “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.